Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey A Engelman

Showing results (11-20 of 189) with videos related to

Pageof 19
Sort By:
Cancer Cell|May 6, 2008
A sweet new role for EGFR in cancerJeffrey A Engelman, Lewis C Cantley
Science Signaling|September 26, 2013
Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancerMatthew J Niederst, Jeffrey A Engelman
Cancer Cell|March 22, 2014
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeuticsCarlos L Arteaga, Jeffrey A Engelman
The New England Journal of Medicine|May 5, 2016
Crizotinib Resensitization by Compound MutationAlice T Shaw, Jeffrey A Engelman
Cancer Cell|March 24, 2012
SnapShot: non-small cell lung cancerRebecca S Heist, Jeffrey A Engelman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitorsJeffrey A Engelman, Lewis C Cantley
Nature Reviews. Genetics|July 19, 2006
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismJeffrey A Engelman, Ji Luo, Lewis C Cantley
Cancer Discovery|May 16, 2012
A new BATTLE in the evolving war on cancerLecia V Sequist, Alona Muzikansky, Jeffrey A Engelman
Oncotarget|April 21, 2011
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancersRyan B Corcoran, Jeffrey Settleman, Jeffrey A Engelman
Cell Cycle (Georgetown, Tex.)|February 18, 2010
Differences underlying EGFR and HER2 oncogene addictionAnthony C Faber, Kwok-Kin Wong, Jeffrey A Engelman
Pageof 19

Showing results (11-20 of 189) with videos related to

Sort By:
Pageof 19
Cancer Cell|May 6, 2008
A sweet new role for EGFR in cancerJeffrey A Engelman, Lewis C Cantley
Science Signaling|September 26, 2013
Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancerMatthew J Niederst, Jeffrey A Engelman
Cancer Cell|March 22, 2014
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeuticsCarlos L Arteaga, Jeffrey A Engelman
The New England Journal of Medicine|May 5, 2016
Crizotinib Resensitization by Compound MutationAlice T Shaw, Jeffrey A Engelman
Cancer Cell|March 24, 2012
SnapShot: non-small cell lung cancerRebecca S Heist, Jeffrey A Engelman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitorsJeffrey A Engelman, Lewis C Cantley
Nature Reviews. Genetics|July 19, 2006
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismJeffrey A Engelman, Ji Luo, Lewis C Cantley
Cancer Discovery|May 16, 2012
A new BATTLE in the evolving war on cancerLecia V Sequist, Alona Muzikansky, Jeffrey A Engelman
Oncotarget|April 21, 2011
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancersRyan B Corcoran, Jeffrey Settleman, Jeffrey A Engelman
Cell Cycle (Georgetown, Tex.)|February 18, 2010
Differences underlying EGFR and HER2 oncogene addictionAnthony C Faber, Kwok-Kin Wong, Jeffrey A Engelman
Pageof 19